Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) with or without Metformin

X
Trial Profile

A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) with or without Metformin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirzepatide (Primary) ; Insulin glargine; Insulin lispro; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SURPASS-6
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 06 Oct 2023 Primary endpoint Change from Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) has been met according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
    • 06 Oct 2023 Results assessing Efficacy and safety of TZP vs insulin lispro (iLispro) was assessed in people with T2D with inadequately controlled glycemic control on insulin glargine and metformin presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top